strong result rais sale ep estim year
deeper look humira ex-u trend suggest concern around guid
overdon continu view excit new product stori upward
revis possibl sever front stock attract valu versu group
ep estim vs consensu guidanc
intact estim rais dime vs consensu
vs consensu forecast
remain intact ep compound-annual-growth-rate increas
ep compound-annual-growth-rate unchang guidanc look double-digit ep growth
ep growth humira patent expir howev
lower target price ep pend visibl new
product rollout and/or degre humira ou eros
sale forecast vs consensu guidanc cer
intact project rais vs consensu
guidanc sale compound-annual-growth-rate
increas sale compound-annual-growth-rate unchang
earn call guid ou humira sale
estim time caus good deal investor concern regard
abil hit guidanc ou humira declin howev deeper
analysi see page suggest guidanc fulli achiev split ou sale
geographi biosimilar approxim ou humira
sale face direct biosimilar competit
biosimilar foreign market includ australia brazil canada japan patent
protect sale growth constant currenc basi segment
isnt face biosimilar competit forecast low-to-mid singl digit
compris high-singl volum off-set neg price
bottom line achiev guidanc ou humira sale eu
region face biosimilar threat could much
assum ou region threaten biosimilar grow
sale region biosimilar compet could declin ou humira revenu
still could total
oper margin forecast intact compar guidanc
estim vs guidanc lower
project intact
pleas see page report import disclosur
provid long-term guidanc expect humira appear
solid foot forese futur competit posit
hepat segment oncolog compani pipelin promis
agent opportun upward revis sever front stock
attract valu versu group overal attribut argu purchas
upadacitinib approv ra
humira sale trend particularli
orilissa uptak endometriosi uterin
humira sale
humira biosimilar eros less
especi oncolog immunolog
 bolster long-term visibl
humira erod quickli
expect eu and/or launch
oncolog immunolog product
global biopharmaceut compani product use treat rheumatoid
arthriti psoriasi crohn ulcer coliti hcv hematolog tumor among other
humira ra crohn domin product repres total sale
profit also pipelin compound indic phase ii
phase develop
cowen compani
compani data cowen compani
compani data cowen compani
ww foreign lc ex foreign sale report portion foreign leuprolid foreign lc ex leuprolid foreign lc ex cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
ww ip expect hold till post settlement launch later humira biosimilar launch eu declin year expect foreign lc ex ra pa crohn psoriasi jai uc uveiti hshumira adalimumab anti-tnf mab guidanc approach guidanc peak record sale foreign sale report includ sale total portion foreign record share ou profitsimbruvica approv hematolog cancer pcyc acq close acquir solvay pacrealipas enzym replac pancreat insufficiencysynthroid steadi sale gener difficult formul synthroid levothyroxin overact thyroidlupron leuprolid line extens support foreign lc ex leuprolid gener avail lupron still lead market mo depotsynagi foreign lc ex human mab bind f-protein rsvdepakot divalproex acid seizur control bipolar mania ir patent expir er patent expir cowen
compani data cowen compani
 patent expir maintain share via servic foreign lc ex induct mainten gener anesthesiaultane/sevofluoran flourin isopropyl ether anesthesiaandrogel gener form launchedandrogel testosteron gel hypergonad market declin gener pressurekaletra lopinavir/low-dos ritonavir combo hiv patent exp market em aluvia combo proteas inhibitor foreign lc ex emerg market slow sale declinenorvir patent expir januari inhibit cytochrom metabol pi foreign lc ex ritonavir hiv proteas inhibitor use booster combozemplar teva gener launch foreign lc ex paricalcitol tx secondari hyperparathyroid pt ckftricor/trilipix gener launch gener launch via settlement teva/brl foreign lc ex er niacin rais hdl reduc ldlother includ gross-to-net adjust assum ceas humira patent us includ nimbex vicodin etc emerg mkt growth foreign lc ex cowen
compani data cowen compani
 combin glecaprevir pi pibrentasvir hcv dose tablet qd week eign lc ex all-or regimen genotyp ifn-nav hcv patientsmavyret patient without cirrhosi new treatmentviekirax exviera combin paritaprebir/r pi ombitasvir inhibitor dasabuvir non-nuc polymeras inhibitor hcv eign lc ex all-or regimen genotyp ifn-nav hcv patientsviekirax exviera ww guidanc profit roch incom line royalti estimate sale roch condit eu approv eign lc ex approv cll delet r/r cll rituxanvenclexta venetoclax select inhibitor cllorilissa- oral gnrh antagonist partial estrogen suppress endometriosi approv uterin fibroib file partnership neurocrin eign lc ex similar lupron zoladexelagolix hold ww right orilissa gnrh antagonistsrova-t meru sclc mainten complet stop futil eign lc ex stem cell technolog solid tumor target peak salesrova-t stemcentrx acq conting payment close rizankizumab guidanc approv psoriasi ph crohn uc ph ii eign lc ex month bi bi receiv mileston royaltiesduodopa infus directli small intestin via portabl pump like nich product refractori pd eign lc ex market solvay ousduodopa gel formul carbidopa/levodopa parkinson supadacitinib- guidanc ra file ph atop dermat ph ii axspa gca eign lc ex jak inhibitor competit profil ra crohn uc ad cowen
compani data cowen compani
 partner record profit record royalti ex-u foreign lc ex elotuzumab antibodi multipl myeloma r/r mm w/poma dexdepatux-m ph gbm fail gbm foreign lc ex bid oral dose cross bbb foreign lc ex parp inhibitor ovarian cancer phase zinbryta foreign lc ex fx zinbryta daclizumab withdrawn global march foreign lc ex foreign lc ex guidanc annual revenu growth cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ heavi depend humira sale ep success pipelin
product notabl hepat portfolio success independ compani
